This week, the overall grades of five Medical Devices stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Navidea Biopharmaceuticals (AMEX:NAVB) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Navidea Biopharmaceuticals is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, NAVB also gets F’s. As of Oct. 1, 2012, 15.7% of outstanding Navidea Biopharmaceuticals shares were held short. For more information, get Portfolio Grader’s complete analysis of NAVB stock.
AngioDynamics (NASDAQ:ANGO) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). AngioDynamics is a developer and manufacturer of gastrointestinal contrast agents and related imaging accessories. The stock also gets an F in Margin Growth. For a full analysis of ANGO stock, visit Portfolio Grader.
This is a rough week for Baxter International (NYSE:BAX). The company’s rating falls to D from the previous week’s C. Baxter International develops, manufactures and markets products related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. To get an in-depth look at BAX, get Portfolio Grader’s complete analysis of BAX stock.
The rating of Greatbatch (NYSE:GB) declines this week from a C to a D. Greatbatch develops and manufactures power sources, feedthroughs, and wet tantalum capacitors used in implantable medical devices. The stock’s trailing PE Ratio is 27.30. For a full analysis of GB stock, visit Portfolio Grader.
The rating of Hansen Medical (NASDAQ:HNSN) slips from a D to a F. Hansen Medical develops and manufactures medical robotics designed for positioning, manipulation, and control of catheters and catheter-based technologies. The stock gets F’s in Equity, Cash Flow, and Sales Growth. As of Oct. 1, 2012, 16.1% of outstanding Hansen Medical shares were held short. For more information, get Portfolio Grader’s complete analysis of HNSN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.